NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma
Updated: Feb 10
NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cells, manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed and refractory multiple myeloma
Sponsor
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT05172596
Official Title: Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma
First Posted : December 29, 2021
Click here to see details on ClinicalTrials.gov
Biological: PHE885
Autologous Anti-BCMA CAR T-cells PHE885 (Code C174124)
Autologous Anti-BCMA CAR T-cells PHE885
Autologous BCMA-specific CAR T-cells PHE885
BCMA-directed Autologous CAR-T Cells PHE885
PHE 885
PHE-885
PHE885
Locations
Australia, Melbourne
Singapore
Comments